+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Disease Management Market By Type, By Disease Type, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 281 Pages
  • July 2022
  • Region: Global
  • Allied Market Research
  • ID: 5671046
The global chronic disease management market was valued at $4,896.69 million in 2021 and is projected to reach $14,875.48 million by 2031, registering a CAGR of 11.8% from 2022 to 2031.

Chronic disease management is an integrated care approach to managing the illness, which includes screenings, check-ups, monitoring and coordinating treatment, and patient education. It can improve the quality of life, while reducing healthcare costs. Chronic disease management programs are designed to improve the health of individuals with chronic conditions and reduce associated costs from avoidable complications by identifying and treating chronic conditions more quickly and more effectively; thus slowing the progression of those diseases.

The key factors that drive the growth of the market are an increase in awareness regarding the healthcare management service and a rise in the prevalence of chronic diseases such as cancer, heart disease, diabetes, high blood pressure, and others. According to a report published by the World Health Organization, in 2021, non-communicable diseases (NCDs) killed around 41 million people each year, which was 71% of all deaths globally. Moreover, improved services by the service provider have increased the demand for chronic disease management services in the market. The growth in the medical tourism sector and the rise in healthcare IT solutions drive the growth of the chronic disease management market. However, a lack of skilled professionals and high cost of treatment, and high investment in the management system/tools hinder the growth of the market.

The chronic disease management market is segmented on the basis of type, disease type, end user, and region. By type, the market is bifurcated into solutions and services. The solution segment is further classified on the basis of an on-premise solution and a cloud-based solution. On the basis of service, the segment is segmented into educational service, implementation service, and consulting service. On the basis of disease type, the segment is divided into cardiovascular disease, diabetes, cancer, asthma, a chronic obstructive pulmonary disorder, and others. On the basis of end-user, the segment is divided into providers, payers, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the chronic disease management market share in 2021 and is anticipated to remain dominant during the forecast period. The factors, such as favorable regulatory scenario, pressure on healthcare institutions to reduce costs, and rise in trends in healthcare IT, big data and cloud computing, well-established healthcare infrastructure, continuous reforms by governments, and an increase in diseased patient burden are driving the growth of the chronic disease management market in the regions.

For instance, the U.S. government implemented the Affordable Care Act (ACA) for the prevention of diseases and the adoption of healthcare IT. The ACA is expected to boost the growth of the chronic disease management market and create opportunities for population health management service providers to collect and maintain patients’ data.

The key players that operate in the chronic disease management market are WellSky, ZeOmega, Health Catalyst, Cedar Gate Technologies, Cognizant, Pegasystems Inc., Epic Systems Corporation, Hinduja Global Solutions Ltd. (Bengaluru), NXGN Management, LLC, MINES & Associates, Inc., Casenet, LLC, ExlServings Holdings, Inc., cliexa., ScienceSoft USA Corporation, Vivify Health, Inc., Allscripts Healthcare, LLC, Infosys Limited, Medecision, IBM, Altruista Health, TCS Healthcare Technologies, and Koninklijke Philips N.V. (Netherlands

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic disease management market analysis from 2021 to 2031 to identify the prevailing chronic disease management market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the chronic disease management market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global chronic disease management market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Cardiovascular diseases
  • Diabetes
  • Cancer
  • Asthma
  • Chronic obstructive pulmonary disorders
  • Others

By Type

  • Solutions
  • Services

By End User

  • Healthcare Providers
  • Healthcare Payers
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Italy
  • Spain
  • Rest of Europe
  • Germany
  • France
  • U.K.
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest Of Asia Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Koninklijke Philips N.V
  • Cognizant TriZetto Software Group Inc
  • Cedar Gate Technologies
  • Casenet, LLC
  • cliexa, Inc
  • Altruista Health
  • Infosys Ltd
  • Pegasystems Inc
  • Epic Systems Corporation
  • Hinduja Global Solutions Ltd
  • NXGN Management, LLC
  • ExlServings Holdings, Inc
  • Vivify Health, Inc
  • Allscripts Healthcare, LLC
  • Medecision
  • ZeOmega
  • Health Catalyst
Frequently Asked Questions about the Global Chronic Disease Management Market

What is the estimated value of the Global Chronic Disease Management Market?

The Global Chronic Disease Management Market was estimated to be valued at $4896.69 million in 2021.

What is the growth rate of the Global Chronic Disease Management Market?

The growth rate of the Global Chronic Disease Management Market is 11.8%, with an estimated value of $14875.48 million by 2031.

What is the forecasted size of the Global Chronic Disease Management Market?

The Global Chronic Disease Management Market is estimated to be worth $14875.48 million by 2031.

Who are the key companies in the Global Chronic Disease Management Market?

Key companies in the Global Chronic Disease Management Market include Koninklijke Philips N.V, Cognizant Trizetto Software Group Inc,, Cedar Gate Technologies, Casenet, LLC, Cliexa, Inc, Altruista Health, Infosys Ltd, Pegasystems Inc, Epic Systems Corporation and Hinduja Global Solutions Ltd.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Solutions
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Services
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Cardiovascular diseases
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Diabetes
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Cancer
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Asthma
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Chronic obstructive pulmonary disorders
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 Others
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
CHAPTER 6: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Healthcare Providers
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Healthcare Payers
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: CHRONIC DISEASE MANAGEMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Disease Type
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Disease Type
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Disease Type
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Disease Type
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Disease Type
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Disease Type
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Disease Type
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Disease Type
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Disease Type
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Disease Type
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Disease Type
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Disease Type
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Disease Type
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Disease Type
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Disease Type
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Disease Type
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Disease Type
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest Of Asia Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Disease Type
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Disease Type
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Disease Type
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Disease Type
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Disease Type
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Disease Type
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Koninklijke Philips N.V
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Cognizant TriZetto Software Group Inc,
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Cedar Gate Technologies
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Casenet, LLC
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 cliexa, Inc
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Altruista Health
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Infosys Ltd
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Pegasystems Inc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Epic Systems Corporation
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Hinduja Global Solutions Ltd
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 NXGN Management, LLC
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 ExlServings Holdings, Inc
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Vivify Health, Inc
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Allscripts Healthcare, LLC
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Medecision
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 ZeOmega
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Health Catalyst
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments
List of Tables
Table 1. Global Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 2. Chronic Disease Management Market Size, for Solutions, by Region, 2021-2031 ($Million)
Table 3. Chronic Disease Management Market for Solutions, by Country, 2021-2031 ($Million)
Table 4. Chronic Disease Management Market Size, for Services, by Region, 2021-2031 ($Million)
Table 5. Chronic Disease Management Market for Services, by Country, 2021-2031 ($Million)
Table 6. Global Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 7. Chronic Disease Management Market Size, for Cardiovascular Diseases , by Region, 2021-2031 ($Million)
Table 8. Chronic Disease Management Market for Cardiovascular Diseases , by Country, 2021-2031 ($Million)
Table 9. Chronic Disease Management Market Size, for Diabetes, by Region, 2021-2031 ($Million)
Table 10. Chronic Disease Management Market for Diabetes, by Country, 2021-2031 ($Million)
Table 11. Chronic Disease Management Market Size, for Cancer, by Region, 2021-2031 ($Million)
Table 12. Chronic Disease Management Market for Cancer, by Country, 2021-2031 ($Million)
Table 13. Chronic Disease Management Market Size, for Asthma, by Region, 2021-2031 ($Million)
Table 14. Chronic Disease Management Market for Asthma, by Country, 2021-2031 ($Million)
Table 15. Chronic Disease Management Market Size, for Chronic Obstructive Pulmonary Disorders, by Region, 2021-2031 ($Million)
Table 16. Chronic Disease Management Market for Chronic Obstructive Pulmonary Disorders, by Country, 2021-2031 ($Million)
Table 17. Chronic Disease Management Market Size, for Others, by Region, 2021-2031 ($Million)
Table 18. Chronic Disease Management Market for Others, by Country, 2021-2031 ($Million)
Table 19. Global Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 20. Chronic Disease Management Market Size, for Healthcare Providers, by Region, 2021-2031 ($Million)
Table 21. Chronic Disease Management Market for Healthcare Providers, by Country, 2021-2031 ($Million)
Table 22. Chronic Disease Management Market Size, for Healthcare Payers, by Region, 2021-2031 ($Million)
Table 23. Chronic Disease Management Market for Healthcare Payers, by Country, 2021-2031 ($Million)
Table 24. Chronic Disease Management Market Size, for Others, by Region, 2021-2031 ($Million)
Table 25. Chronic Disease Management Market for Others, by Country, 2021-2031 ($Million)
Table 26. Chronic Disease Management Market, by Region, 2021-2031 ($Million)
Table 27. North America Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 28. North America Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 29. North America Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 30. North America Chronic Disease Management Market, by Country, 2021-2031 ($Million)
Table 31. U.S. Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 32. U.S. Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 33. U.S. Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 34. Canada Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 35. Canada Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 36. Canada Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 37. Mexico Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 38. Mexico Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 39. Mexico Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 40. Europe Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 41. Europe Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 42. Europe Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 43. Europe Chronic Disease Management Market, by Country, 2021-2031 ($Million)
Table 44. Germany Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 45. Germany Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 46. Germany Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 47. France Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 48. France Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 49. France Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 50. U.K. Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 51. U.K. Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 52. U.K. Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 53. Italy Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 54. Italy Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 55. Italy Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 56. Spain Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 57. Spain Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 58. Spain Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 59. Rest of Europe Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 60. Rest of Europe Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 61. Rest of Europe Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 62. Asia-Pacific Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 63. Asia-Pacific Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 64. Asia-Pacific Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 65. Asia-Pacific Chronic Disease Management Market, by Country, 2021-2031 ($Million)
Table 66. Japan Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 67. Japan Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 68. Japan Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 69. China Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 70. China Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 71. China Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 72. Australia Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 73. Australia Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 74. Australia Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 75. India Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 76. India Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 77. India Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 78. South Korea Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 79. South Korea Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 80. South Korea Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 81. Rest of Asia-Pacific Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 82. Rest of Asia-Pacific Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 83. Rest of Asia-Pacific Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 84. LAMEA Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 85. LAMEA Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 86. LAMEA Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 87. LAMEA Chronic Disease Management Market, by Country, 2021-2031 ($Million)
Table 88. Brazil Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 89. Brazil Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 90. Brazil Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 91. Saudi Arabia Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 92. Saudi Arabia Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 93. Saudi Arabia Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 94. South Africa Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 95. South Africa Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 96. South Africa Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 97. Rest of LAMEA Chronic Disease Management Market, by Type, 2021-2031 ($Million)
Table 98. Rest of LAMEA Chronic Disease Management Market, by Disease Type, 2021-2031 ($Million)
Table 99. Rest of LAMEA Chronic Disease Management Market, by End-user, 2021-2031 ($Million)
Table 100. Koninklijke Philips N.V: Company Snapshot
Table 101. Koninklijke Philips N.V: Operating Segments
Table 102. Koninklijke Philips N.V: Product Portfolio
Table 103. Koninklijke Philips N.V: Net Sales
Table 104. Koninklijke Philips N.V: Key Stratergies
Table 105. Cognizant Trizetto Software Group Inc,: Company Snapshot
Table 106. Cognizant Trizetto Software Group Inc,: Operating Segments
Table 107. Cognizant Trizetto Software Group Inc,: Product Portfolio
Table 108. Cognizant Trizetto Software Group Inc,: Net Sales
Table 109. Cognizant Trizetto Software Group Inc,: Key Stratergies
Table 110. Cedar Gate Technologies: Company Snapshot
Table 111. Cedar Gate Technologies: Operating Segments
Table 112. Cedar Gate Technologies: Product Portfolio
Table 113. Cedar Gate Technologies: Net Sales
Table 114. Cedar Gate Technologies: Key Stratergies
Table 115. Casenet, LLC: Company Snapshot
Table 116. Casenet, LLC: Operating Segments
Table 117. Casenet, LLC: Product Portfolio
Table 118. Casenet, LLC: Net Sales
Table 119. Casenet, LLC: Key Stratergies
Table 120. Cliexa, Inc: Company Snapshot
Table 121. Cliexa, Inc: Operating Segments
Table 122. Cliexa, Inc: Product Portfolio
Table 123. Cliexa, Inc: Net Sales
Table 124. Cliexa, Inc: Key Stratergies
Table 125. Altruista Health: Company Snapshot
Table 126. Altruista Health: Operating Segments
Table 127. Altruista Health: Product Portfolio
Table 128. Altruista Health: Net Sales
Table 129. Altruista Health: Key Stratergies
Table 130. Infosys Ltd: Company Snapshot
Table 131. Infosys Ltd: Operating Segments
Table 132. Infosys Ltd: Product Portfolio
Table 133. Infosys Ltd: Net Sales
Table 134. Infosys Ltd: Key Stratergies
Table 135. Pegasystems Inc: Company Snapshot
Table 136. Pegasystems Inc: Operating Segments
Table 137. Pegasystems Inc: Product Portfolio
Table 138. Pegasystems Inc: Net Sales
Table 139. Pegasystems Inc: Key Stratergies
Table 140. Epic Systems Corporation: Company Snapshot
Table 141. Epic Systems Corporation: Operating Segments
Table 142. Epic Systems Corporation: Product Portfolio
Table 143. Epic Systems Corporation: Net Sales
Table 144. Epic Systems Corporation: Key Stratergies
Table 145. Hinduja Global Solutions Ltd: Company Snapshot
Table 146. Hinduja Global Solutions Ltd: Operating Segments
Table 147. Hinduja Global Solutions Ltd: Product Portfolio
Table 148. Hinduja Global Solutions Ltd: Net Sales
Table 149. Hinduja Global Solutions Ltd: Key Stratergies
Table 150. Nxgn Management, LLC: Company Snapshot
Table 151. Nxgn Management, LLC: Operating Segments
Table 152. Nxgn Management, LLC: Product Portfolio
Table 153. Nxgn Management, LLC: Net Sales
Table 154. Nxgn Management, LLC: Key Stratergies
Table 155. Exlservings Holdings, Inc: Company Snapshot
Table 156. Exlservings Holdings, Inc: Operating Segments
Table 157. Exlservings Holdings, Inc: Product Portfolio
Table 158. Exlservings Holdings, Inc: Net Sales
Table 159. Exlservings Holdings, Inc: Key Stratergies
Table 160. Vivify Health, Inc: Company Snapshot
Table 161. Vivify Health, Inc: Operating Segments
Table 162. Vivify Health, Inc: Product Portfolio
Table 163. Vivify Health, Inc: Net Sales
Table 164. Vivify Health, Inc: Key Stratergies
Table 165. Allscripts Healthcare, LLC: Company Snapshot
Table 166. Allscripts Healthcare, LLC: Operating Segments
Table 167. Allscripts Healthcare, LLC: Product Portfolio
Table 168. Allscripts Healthcare, LLC: Net Sales
Table 169. Allscripts Healthcare, LLC: Key Stratergies
Table 170. Medecision: Company Snapshot
Table 171. Medecision: Operating Segments
Table 172. Medecision: Product Portfolio
Table 173. Medecision: Net Sales
Table 174. Medecision: Key Stratergies
Table 175. Zeomega: Company Snapshot
Table 176. Zeomega: Operating Segments
Table 177. Zeomega: Product Portfolio
Table 178. Zeomega: Net Sales
Table 179. Zeomega: Key Stratergies
Table 180. Health Catalyst: Company Snapshot
Table 181. Health Catalyst: Operating Segments
Table 182. Health Catalyst: Product Portfolio
Table 183. Health Catalyst: Net Sales
Table 184. Health Catalyst: Key Stratergies
List of Figures
Figure 1. Chronic Disease Management Market Segmentation
Figure 2. Chronic Disease Management Market,2021-2031
Figure 3. Chronic Disease Management Market,2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Chronic Disease Management Market:Drivers, Restraints and Opportunities
Figure 12. Chronic Disease Management Market,By Type,2021(%)
Figure 13. Comparative Share Analysis of Solutions Chronic Disease Management Market,2021-2031(%)
Figure 14. Comparative Share Analysis of Services Chronic Disease Management Market,2021-2031(%)
Figure 15. Chronic Disease Management Market,By Disease Type,2021(%)
Figure 16. Comparative Share Analysis of Cardiovascular Diseases Chronic Disease Management Market,2021-2031(%)
Figure 17. Comparative Share Analysis of Diabetes Chronic Disease Management Market,2021-2031(%)
Figure 18. Comparative Share Analysis of Cancer Chronic Disease Management Market,2021-2031(%)
Figure 19. Comparative Share Analysis of Asthma Chronic Disease Management Market,2021-2031(%)
Figure 20. Comparative Share Analysis of Chronic Obstructive Pulmonary Disorders Chronic Disease Management Market,2021-2031(%)
Figure 21. Comparative Share Analysis of Others Chronic Disease Management Market,2021-2031(%)
Figure 22. Chronic Disease Management Market,By End-user,2021(%)
Figure 23. Comparative Share Analysis of Healthcare Providers Chronic Disease Management Market,2021-2031(%)
Figure 24. Comparative Share Analysis of Healthcare Payers Chronic Disease Management Market,2021-2031(%)
Figure 25. Comparative Share Analysis of Others Chronic Disease Management Market,2021-2031(%)
Figure 26. Chronic Disease Management Market by Region,2021
Figure 27. U.S. Chronic Disease Management Market,2021-2031($Million)
Figure 28. Canada Chronic Disease Management Market,2021-2031($Million)
Figure 29. Mexico Chronic Disease Management Market,2021-2031($Million)
Figure 30. Germany Chronic Disease Management Market,2021-2031($Million)
Figure 31. France Chronic Disease Management Market,2021-2031($Million)
Figure 32. U.K. Chronic Disease Management Market,2021-2031($Million)
Figure 33. Italy Chronic Disease Management Market,2021-2031($Million)
Figure 34. Spain Chronic Disease Management Market,2021-2031($Million)
Figure 35. Rest of Europe Chronic Disease Management Market,2021-2031($Million)
Figure 36. Japan Chronic Disease Management Market,2021-2031($Million)
Figure 37. China Chronic Disease Management Market,2021-2031($Million)
Figure 38. Australia Chronic Disease Management Market,2021-2031($Million)
Figure 39. India Chronic Disease Management Market,2021-2031($Million)
Figure 40. South Korea Chronic Disease Management Market,2021-2031($Million)
Figure 41. Rest of Asia-Pacific Chronic Disease Management Market,2021-2031($Million)
Figure 42. Brazil Chronic Disease Management Market,2021-2031($Million)
Figure 43. Saudi Arabia Chronic Disease Management Market,2021-2031($Million)
Figure 44. South Africa Chronic Disease Management Market,2021-2031($Million)
Figure 45. Rest of LAMEA Chronic Disease Management Market,2021-2031($Million)
Figure 46. Top Winning Strategies, by Year
Figure 47. Top Winning Strategies, by Development
Figure 48. Top Winning Strategies, by Company
Figure 49. Product Mapping of Top 10 Players
Figure 50. Competitive Dashboard
Figure 51. Competitive Heatmap of Top 10 Key Players
Figure 52. Koninklijke Philips N.V.: Net Sales ,($Million)
Figure 53. Cognizant Trizetto Software Group Inc,.: Net Sales ,($Million)
Figure 54. Cedar Gate Technologies.: Net Sales ,($Million)
Figure 55. Casenet, LLC.: Net Sales ,($Million)
Figure 56. Cliexa, Inc.: Net Sales ,($Million)
Figure 57. Altruista Health.: Net Sales ,($Million)
Figure 58. Infosys Ltd.: Net Sales ,($Million)
Figure 59. Pegasystems Inc.: Net Sales ,($Million)
Figure 60. Epic Systems Corporation.: Net Sales ,($Million)
Figure 61. Hinduja Global Solutions Ltd.: Net Sales ,($Million)
Figure 62. Nxgn Management, LLC.: Net Sales ,($Million)
Figure 63. Exlservings Holdings, Inc.: Net Sales ,($Million)
Figure 64. Vivify Health, Inc.: Net Sales ,($Million)
Figure 65. Allscripts Healthcare, LLC.: Net Sales ,($Million)
Figure 66. Medecision.: Net Sales ,($Million)
Figure 67. Zeomega.: Net Sales ,($Million)
Figure 68. Health Catalyst.: Net Sales ,($Million)

Executive Summary

According to the report, titled, “Chronic Disease Management Market," the Chronic Disease Management Market size was valued at $4.90 billion in 2021, and is estimated to reach $14.88 billion by 2031, growing at a CAGR of 11.8% from 2022 to 2031.

Chronic diseases are long-term progressive ailments that are among the most expensive and common healthcare challenges in the world. Chronic disease management is a sort of digital healthcare service that assists healthcare providers in providing educational information to their patients and the implementation of patient- and illness-specific treatment alternatives and regimens. These services are specifically developed to help people manage chronic conditions and lessen their severity.

The Chronic Disease Management Market trends are an increase in awareness regarding healthcare management services and a rise in the prevalence of chronic diseases such as asthma, COPD, cancer, diabetes, stroke or musculoskeletal diseases across the globe. Moreover, improved services by service providers have increased the demand for chronic disease management services in the market. The growth in the medical tourism sector and the rise in healthcare IT solutions drive the Chronic Disease Management Market growth. However, a lack of skilled professional and high cost of treatment, and high investment in the management system/tools hinders the growth of the market.

COVID-19 Impact

Coronavirus (COVID-19) was discovered in late December 2019, in the Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. Furthermore, the virus has high potential of lethality in the geriatric population. On March 11, 2020, the World Health Organization assessed that COVID-19 can be characterized as a pandemic.

The overall impact of COVID-19 remains positive on the chronic disease management market. As the increase in the prevalence of COVID-19 has driven the demand for accurate diagnosis and treatment devices in several countries. In this regard, chronic disease management solutions have proven to be very helpful, as they allow healthcare providers to seamlessly integrate solutions such as EHR, patient management, and care management to healthcare payer solutions such as claim management and payment management solutions. Moreover, the rapid spread of this disease worldwide has resulted in lockdowns and restrictions, thereby increasing the demand for electronic data transfer and claim management. This is expected to increase the adoption of chronic disease management in the coming years as well.

On the basis of type, the chronic disease management market has been segmented into solutions and services. In 2021, the solution segment accounted for the largest share of the market. The dominance of this segment can be attributed to the increased adoption of software solutions by payers and providers to reduce readmissions, increase cost-effectiveness, improve operational efficiency, enhance patient engagement, and aid data integration and analysis.

On the basis of application, the diabetes segment exhibited the highest growth in 2021 and is anticipated to lead during the forecast period, owing to an increase in the prevalence of type 1 and type 2 diabetes across the world.

Depending on the end user the chronic disease management market is segmented into healthcare providers, healthcare payers, and others. In 2021, the healthcare providers segment accounted for the largest share of 48.0%. The large share of this segment was attributed to the implementation of the Affordable Care Act and Hospital Readmissions Reduction Program (aimed at lowering healthcare costs by using novel population health management solutions) in the U.S., as well as high demand for these solutions among healthcare providers across regions.

The Chronic Disease Management Industry is segmented on the basis of type, disease type, end user, and region. By type, the market is segmented into solutions and services. The solution segment is further classified on the basis of an on-premise solution and cloud-based solutions. On the basis of service, the segment is categorized into educational service, implementation service, and consulting service. On the basis of disease type, the segment is divided into cardiovascular disease, diabetes, cancer, asthma, a chronic obstructive pulmonary disorder, and others. On the basis of end-user, the segment is divided into providers, payers, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the chronic disease management market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to rising in the number of chronic disease cases, the presence of key players, and advancements in healthcare in the region. For instance, six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes which are leading causes of death and disability and they are also a leading driver of the healthcare costs in this region.

Asia-Pacific is anticipated to witness lucrative growth, owing to an increase in medical tourism, implementation of new ICT guidelines in Japan, investments, and reforms to modernize China’s healthcare infrastructure, rapid growth in the healthcare industry in India, and the implementation of IT programs in Australia and New Zealand. In addition, government initiatives for the adoption of HCIT, the growth in geriatric population, rise in prevalence of chronic diseases, increase in healthcare expenditure, and rise in purchasing power of consumers are also expected to support the market growth in this region.

The key players that operate in the chronic disease management market are ZeOmega, Health Catalyst, Cedar Gate Technologies, Cognizant, Pegasystems Inc., Epic Systems Corporation, Hinduja Global Solutions Ltd. (Bengaluru), NXGN Management, LLC, Casenet, LLC, ExlServings Holdings, Inc., cliexa, Inc., Vivify Health, Inc., Allscripts Healthcare, LLC, Infosys Limited, Medecision, Altruista Health, Koninklijke Philips N.V. (Netherlands)

Key Findings of the Study

  • By Type, the solution segment was the highest contributor to the market in 2021.
  • By Disease type, the diabetes segment was the highest contributor in 2021.
  • By End user, the healthcare-providers dominated the market in 2021 and is expected to continue this trend during the forecast period.
  • By Region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
.

Companies Mentioned

  • Koninklijke Philips N.V
  • Cognizant Trizetto Software Group Inc,
  • Cedar Gate Technologies
  • Casenet, LLC
  • Cliexa, Inc
  • Altruista Health
  • Infosys Ltd
  • Pegasystems Inc
  • Epic Systems Corporation
  • Hinduja Global Solutions Ltd
  • Nxgn Management, LLC
  • Exlservings Holdings, Inc
  • Vivify Health, Inc
  • Allscripts Healthcare, LLC
  • Medecision
  • Zeomega
  • Health Catalyst

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...